随机对照试验的衰落。 - Suppr | 超能文献

The demise of the randomized controlled trial.

作者信息

Herman J

机构信息

Department of Social Medicine, Hadassah/Hebrew University Medical School, Jerusalem, Israel.

出版信息

J Clin Epidemiol. 1995 Jul;48(7):985-8. doi: 10.1016/0895-4356(94)00203-3.

DOI:10.1016/0895-4356(94)00203-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

The demise of the randomized controlled trial.随机对照试验的衰落。

J Clin Epidemiol. 1995 Jul;48(7):985-8. doi: 10.1016/0895-4356(94)00203-3.

2

Validity of the GUSTO trial's main conclusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronaries.GUSTO试验主要结论的有效性。全球链激酶和组织型纤溶酶原激活剂用于闭塞冠状动脉的研究。

Pharmacotherapy. 1997 Jul-Aug;17(4):850-2.

3

Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.

J Am Coll Cardiol. 1995 Jun;25(7 Suppl):10S-17S. doi: 10.1016/0735-1097(95)00188-a.

4

Tissue plasminogen activator.组织型纤溶酶原激活剂

Br J Hosp Med. 1986 Aug;36(2):87.

5

Tissue-type plasminogen activator for acute coronary thrombosis.用于急性冠状动脉血栓形成的组织型纤溶酶原激活剂。

Med Lett Drugs Ther. 1987 Dec 4;29(754):107-9.

6

Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.组织型纤溶酶原激活剂和链激酶对梗死面积及酶释放速率的不同影响：早期梗死相关动脉通畅的影响。GUSTO酶亚研究

Eur Heart J. 1996 Feb;17(2):237-46. doi: 10.1093/oxfordjournals.eurheartj.a014840.

7

GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last.GUSTO（闭塞动脉中链激酶和组织型纤溶酶原激活剂的全球应用）：逻辑最终获胜。

Eur Heart J. 1994 Jan;15(1):2-4. doi: 10.1093/oxfordjournals.eurheartj.a060374.

8

The rt-PA versus streptokinase. Controversy--I.重组组织型纤溶酶原激活剂与链激酶。争议——I。

J Am Coll Cardiol. 1992 Apr;19(5):1116. doi: 10.1016/0735-1097(92)90305-7.

9

Coronary thrombolysis: second chance therapy--maximizing the advantage.冠状动脉溶栓：二次机会疗法——最大化优势

J Am Coll Cardiol. 1986 Nov;8(5):1218-9. doi: 10.1016/s0735-1097(86)80403-x.

10

[The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].[急性心肌梗死溶栓后再闭塞的预防：组织型纤溶酶原激活剂真的优于链激酶吗？]

G Ital Cardiol. 1995 Apr;25(4):511-5.

引用本文的文献

1

A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis.一项关于皮肤科培训的执业护士对湿疹和银屑病初级护理患者生活质量影响的成本后果研究。

Br J Gen Pract. 2000 Jul;50(456):555-8.

2

Streptokinase versus alteplase in acute myocardial infarction.急性心肌梗死中链激酶与阿替普酶的比较

J R Soc Med. 1996 Aug;89(8):427-30. doi: 10.1177/014107689608900804.